Advertisement

---

JANSSEN RESEARCH & DEVELOPMENT, LLC

Studies Reinforce INVOKANA™ (canagliflozin) (300mg) Provides Greater Improvements in Blood Glucose than Sitagliptin (100 mg) or Glimepiride (6 or 8 mg) in Adults with Type 2 Diabetes

[2013-06-23] - Phase 3 Results for INVOKANA™ Demonstrate Novel Type 2 Diabetes Medicine Also Provided Greater Secondary Endpoint Reductions in Weight and Systolic Blood Pressure
Note: This release corresponds to ADA abstracts 238-OR and 65-LB.


Ibrutinib Data Published in The New England Journal of Medicine Show 68 Percent Overall Response Rate in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)

[2013-06-19] - A second study in relapsed/refractory chronic lymphocytic leukemia (CLL) also published in the online edition


Ibrutinib Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Data Published in The New England Journal of Medicine

[2013-06-19] - A second study in relapsed/refractory mantle cell lymphoma (MCL) also published in the online edition


Latest Data for Type 2 Diabetes Treatment INVOKANA™ (canagliflozin) to be Presented at American Diabetes Association Annual Meeting

[2013-06-18] - Late-Breaking Phase 3 Results and Health Economics Data are Among 17 Accepted Presentations
Note: This release corresponds to ADA abstracts 65-LB, 73-LB, 76-LB, 238-OR, 239-OR, 522-P, 1069-P, 1075-P, 1077-P, 1080-P, 1084-P, 1098-P, 1110-P, 1122-P, 1124-P, 1139-P, 1164-P, 1232-P, 1243-P, 1254-P, 1259-P, 1283-P, and 1565-P.


World Health Organization Issues Interim Guidance on Bedaquiline

[2013-06-17] -


STELARA® Phase 3 Study Published In The Lancet Reports One Year Efficacy And Safety In Treatment Of Active Psoriatic Arthritis

[2013-06-13] - Data Show Interleukin-12/23 Inhibitor STELARA Improved Joint, Soft Tissue and Skin Components of Psoriatic Arthritis


U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C

[2013-05-13] -


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers